Currently, extensively studied are GST polymorphisms that cause reduction or loss of enzymatic activity, i.e., GSTM1, GSTT1, and GSTP1. Reports on relationships between these genetic variants and neoplastic changes suggest their involvement in the etiology of colon, breast, lung, and prostate cancer. Here, GSTM1 is linked to prostate cancer.